Association between MRC criteria and inflammatory parameters.

<p>P value in bold is significantly different (p<0.05).</p

MRC of rats, T2w abdominal images.

<p>Chronic colitis was induced by weekly intrarectal injection of TNBS for 6 weeks. MRC was performed 1 week after the last injection. (A) Axial image of a control rat: colon wall is thin and regular. (B) Coronal image of a chronic TNBS rat: the arrow indicates stenosis with prior dilatation. (C) Axial image of a TNBS rat (T2w with fat suppression): the arrow indicates colon mucosal detachment. (D) Axial image of a TNBS rat: the arrow indicates colon wall thickening.</p

Association between MRC criteria and colon COX-2 expression in rats with chronic colitis.

<p>Chronic colitis was induced in rats by intrarectal injection of TNBS repeated on a weekly basis from day 0 to day 35. MRC was performed at day 42. Maximal and minimal thickness, colon wall signal intensity and luminal narrowing was measured on MR images. Colon COX-2 expression was measured by western blot. Simple linear regression between maximal (A°, minimal (B), colon wall signal intensity (C), luminal narrowing (D) and COX-2 expression. score. Pearson correlation was performed.</p

Association between MRC criteria and fibrosis parameters.

<p>P value in bold is significantly different (p<0.05) while p value in italics represents a trend (0.05</p

Treatments.

<p>m: month. AZA: azathiopurin. 6MP: 6 mercaptopurin. clinical response (+ or-) / mucosal effect (+/-)</p><p>Treatments.</p

Phenotype of lamina propria intestinal lymphocytes.

<p>Phenotype of lamina propria intestinal lymphocytes.</p

Phenotype of peripheral blood lymphocytes.

<p>Phenotype of peripheral blood lymphocytes.</p

H&E staining of the duodenal biopsies of one patient treated with Olmesartan (patient 2) (A, B) and of one patient with AIE (patient 7) (C, D) showing subtotal villous atrophy (A, C: original magnification x 100) with glandular apoptosis (B, D: original magnification x200).

<p>H&E staining of the duodenal biopsies of one patient treated with Olmesartan (patient 2) (A, B) and of one patient with AIE (patient 7) (C, D) showing subtotal villous atrophy (A, C: original magnification x 100) with glandular apoptosis (B, D: original magnification x200).</p

Phenotype of intestinal intraepithelial lymphocytes.

<p>*: excess of CD4+ IEL with onset of CD4 lymphoma after two years treatment with azathioprine (Case published in Malamut et al, ClinGastHepatol 2014); flow cytometry analysis of AIE onset is not available.</p><p>Phenotype of intestinal intraepithelial lymphocytes.</p

Clinical and immune characteristics.

<p>*: detection of serum anti-goblet cells antibodies.</p><p>Ab: antibody. Anti-E: anti-enterocyte Ab. ANA: anti-nuclear Ab. BMI: Body Mass Index. Col: colon. Duod: duodenum. EMA: IgA anti-endomysium. IGA: IgA anti-gliadin. Lymphocytosis: number of intraepithelial lymphocytes for 100 epithelial cells. LC: lymphocytic colitis. LG: lymphocytic gastritis. Sto: stomach. tTG: IgA anti-transglutaminase. VA: villousatrophy. TVA: total villousatrophy. ST VA: sub-totalvillousatrophy. PVA: partial villousatrophy. y: years. Noserum anti-tTG IgG or antigliadin IgG was found. No IgA anti-endomysium was found.</p><p>Clinical and immune characteristics.</p